Trump Proposes Steep Tariffs on Generic Drugs from India
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
What happened
Donald Trump proposed steep tariffs on imported generic drugs, including a 100% levy starting in 2028 and a 200% tariff in 2029. India's pharmaceutical network is a critical pillar of the US healthcare system, supplying around 40% of the 90% of prescriptions dispensed in the United States that are generic. A facility in Hyderabad, for example, produces nearly one billion oral doses monthly, with three-quarters destined for the US market.
From prokerala.com
Why it matters
The tariffs are part of a broader push to expand domestic manufacturing in the US. However, industry executives and healthcare experts note that reshoring production is difficult, as producing most generic medicines in the United States could cost four times more than manufacturing them in India.
Donald Trump's relationship with India drives partnership discussions taking place in Hyderabad.
From prokerala.com
Who's involved
- Donald TrumpProposing tariffs and seeking to expand domestic manufacturing in the US.
- IndiaMajor supplier of generic medicines to the US market.
- HyderabadLocation of a major pharmaceutical manufacturing facility.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- IndiaSpeculative
US tariffs might threaten the core revenue stream of India's generic drug exports.
- FEDSpeculative
Tariffs on essential medicines could introduce supply chain uncertainty and inflationary pressure.
- central governmentSpeculative
The central government might need to manage geopolitical pressure and protect key export industries from US tariffs.
Keep exploring
The entities involved
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
-
Hyderabad
capital of Telangana, India